Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas
2001
Identifying a T-cell Epitope for Colorectal Cancer Immunotherapy
publication
Author Information
Author(s): Tanaka H, Tsunoda T, Nukaya I, Sette A, Matsuda K, Umano Y, Yamaue H, Takesako K, Tanimura H
Primary Institution: Wakayama Medical School, The University of Tokyo, Takara Shuzo Co. Ltd.
Hypothesis
Can the HER2 / neu antigen be used for immunotherapy in colorectal carcinomas?
Conclusion
The HER2 / neu peptide RWGLLLALL may help induce antitumor immunity in colorectal cancer treatment.
Supporting Evidence
- HER2 / neu is linked to poor prognosis in colorectal cancer.
- The peptide RWGLLLALL showed the highest binding affinity to HLA-A24.
- CTLs were induced from CD8+ cells of healthy donors.
Takeaway
Researchers found a piece of a protein that can help the body's immune system fight colorectal cancer.
Methodology
The study involved identifying HLA-A24 binding peptides and inducing CTLs from healthy donors.
Participant Demographics
Healthy donors of HLA-A24 genotype.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website